Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

617 - Biomarkers of malignant cell growth used to assess the risk of osteosarcoma development

Date

11 Sep 2017

Session

Poster display session

Presenters

Bahridil Sultonov

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

B.B. Sultonov1, D. Polatova2, K. Abdikarimov2, U. Islamov2

Author affiliations

  • 1 Muscle-sceletal Oncosurgery, National Cancer Research Center, 100174 - Tashkent/UZ
  • 2 Muscle-sceletal Oncosurgery, National Cancer Research Center, 100002 - Tashkent/UZ
More

Resources

Abstract 617

Background

The aim of our study was a comprehensive study of molecular-genetic, pathologic and clinical symptoms in patients with osteosarcoma to enhance the effectiveness of early diagnosis, treatment and prevention of osteosarcomas.

Methods

We studied the immunophenotypic characteristics of tumor cells in 212 patients with osteosarcoma. Results of antibody reactions to Ki-67, bcl-2, p53 (mutant gene) localized in the nuclei and the mitochondrial matrix expressed in % based on the number of stained cells per 100 examined.

Results

Our results revealed that the expression profile of p53 +, bcl-2-, Ki 67+ in 34.9% (74/212) patients with osteosarcoma is considered as poor prognosis, presented as early metastasis, progression of tumor growth and early relapses (15 months), advanced processes (III and IV stage), low grade pathomorposis (1 and 2), the relative duration of lifespan in patients (up to 3 years), it is associated with a low degree of differentiation (G3), an increase in tumor size up to 550 cm3 with chondroblastic type of osteosarcoma. These data should be considered when looking for and isolating the most promising groups for molecular genetic markers that are would be predictive valuable in the clinic for monitoring the treatment of patients with osteosarcoma.

Conclusions

Thus, it is obvious need for clinical medicine in the implementation and expansion of molecular testing for effective decision-making on the appointment of molecular targeted therapy of patients with osteosarcoma. These requires optimization the approach based on consideration of the specifics of the population, the objective conditions related to the presence of intratumoral characteristics. The data reveals a group of patients with osteosarcoma at high risk with unfavorable prognosis at the stage of examination and choose for these kind of patients effective therapy.

Clinical trial identification

Legal entity responsible for the study

National Cancer Research Center of Uzbekistan

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.